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Abstract
The objective of the study was to determine the
incidence and type of endometrial abnormalities in long term
users of tamoxifen with breast cancer. All patients with a
diagnosis of Oestrogen Receptor positive breast cancer on
Tamoxifen therapy who had also undergone endometrial biopsy
for abnormal bleeding or other symptoms were included.
Among the 37 cases that had long term follow up available,
21(57%) had evidence of endometrial pathology. There were
seven cases of simple hyperplasia and thirteen of endometrial
polyp. Only one case of endometrial carcinoma was seen. These
findings support the association between prolonged tamoxifen
therapy and endometrial pathology of possible neoplastic
potential. Endometrial pathology is dependent on duration of
exposure to Tamoxifen, therefore, close follow up of such
patients is recommended.
Introduction
Tamoxifen is a non steroidal anti-oestrogen and widely
used as an effective hormonal therapy in breast cancer patients.
Long term tamoxifen has been shown to increase the disease
free survival and prevent the relapse of disease and reduce risk
of malignancy in the contra lateral breast.1
Several factors are known to affect endometrial cancer
risk, including reproductive characteristics, obesity, use of
steroid hormone preparations and certain medical conditions
and smoking.1 Exposure to unopposed oestrogen stimulus
whether endogenous or exogenous, substantially increases
women's risk of this disease. Use of combination contraceptive
preparation substantially lowers the risk. Obesity a source of
endogenous (unopposed) oestrogen among post menopausal
women, also increases endometrial cancer risk.1,2
Oestrogen promotes the growth of breast cancer cells.
Tamoxifen works against the effects of oestrogen on these cells.
While Tamoxifen acts against the effects of oestrogen on breast
tissue, by competitively displacing estrogen, it does have weak
intrinsic oestrogenic activity. Tamoxifen has been used for more
than 20 years to treat patients with advanced breast cancer.
There has always been concern regarding the long term
use of tamoxifen therapy and a number of reports have been
published describing tamoxifen use and spectrum of associated
endometrial pathology including endometrial hyperplasia,
endometrial polyps and carcinoma.3
The present study describes endometrial pathology in 37
breast cancer patients on long term tamoxifen treatment that
underwent dilatation and curettage (D& C) for diagnostic purposes. 
Patients, Methods and Results
This case controlled study describes 37 breast cancer
patients treated at Aga Khan University Hospital from 1994 to
1999 who received adjuvant tamoxifen therapy. These patients
underwent sampling by dilatation and curettage for diagnostic
purposes as they presented with either irregular or post
menopausal bleeding per vaginum. These patients were
identified by the indexing and coding unit of the medical record
department of the Aga Khan University.
One patient underwent subsequent hysterectomy one
year after the initial endometrial sampling and the hysterectomy
sample was also available for histological evaluation.
The ages of the patients ranged from 25 to 54 years with
a median age of 52 years. The medical charts of all these
patients were reviewed to collect data regarding age, date and
stage at diagnosis of breast cancer, primary therapy instituted,
estrogen receptor status of primary tumour, dose and duration of
tamoxifen treatment. All the patients' received tamoxifen in a
dose of 20 mg daily. The range of Tamoxifen used was 2-5
years. Median duration of tamoxifen treatment was 22 months.
History of any other hormonal therapy, complaint for which
endometrial sampling was performed and any other risk for
endometrial malignancy was also identified.
Histo-pathological findings of 21 cases that developed
endometrial pathology were compared to 16 cases that did not
develop any pathology.
The histological findings in all the cases are shown in
the table. Among women taking tamoxifen, 57% had evidence
of abnormal endometrium. Tamoxifen treatment was
discontinued after diagnosis of simple hyperplasia and
subsequent hysterectomy done one year later, exhibited normal
secretory endometrium. 
All the cases of simple hyperplasia did not reveal atypia.
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The polyps identified ranged in size 4-6 cms. Histologically
they were composed of hyperplastic endometrial glands and
thick walled vascular channels. Only one case of endometrial
carcinoma was diagnosed. 
Conclusion
Adequate clinical follow up of these patients with
hysteroscopy and endometrial sampling may help in preventing
or assist in early diagnosis of pre neoplastic or neoplastic
processes in the endometrium even in asymptomatic patients. 
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Table: Histological findings of patients with endometrial pathology.
Type of uterine pathology No of cases Percentage
Endometrial Polyp 13 62%
Simple Hyperplasia 07 33%
Complex Hyperplasia 0 0%
Carcinoma 1 3%
Total Abnormal Cases 21 100%
